Fukagawa M - Search Results

1

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.

Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Tsuruya K, et al. Among authors: fukagawa m. Clin Exp Nephrol. 2019 Jun;23(6):739-748. doi: 10.1007/s10157-019-01692-y. Epub 2019 Apr 6. Clin Exp Nephrol. 2019. PMID: 30955188 Free PMC article. Clinical Trial.

2

Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients.

Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kakuta T, Onoda N, Koiwa F, Yumita S, Kurokawa K; Japanese Society for Parathyroid Intervention. Fukagawa M, et al. Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:iii31-3. doi: 10.1093/ndt/gfg1008. Nephrol Dial Transplant. 2003. PMID: 12771296

3

Extracorporeal albumin dialysis.

Abe T, Shono M, Kodama T, Kita Y, Fukagawa M, Akizawa T. Abe T, et al. Among authors: fukagawa m. Ther Apher Dial. 2004 Jun;8(3):217-22. doi: 10.1111/j.1526-0968.2004.00148.x. Ther Apher Dial. 2004. PMID: 15154874

4

How to apply and adapt international guidelines on bone metabolism and disease to the management of Japanese dialysis patients.

Fukagawa M, Akizawa T. Fukagawa M, et al. Ther Apher Dial. 2005 Feb;9(1):1-2. doi: 10.1111/j.1774-9987.2005.00204.x. Ther Apher Dial. 2005. PMID: 15828896 No abstract available.

5

Calcium abnormalities of dialysis patients.

Fukagawa M, Akizawa T. Fukagawa M, et al. J Bone Miner Metab. 2006;24(2):160. doi: 10.1007/s00774-005-0663-y. J Bone Miner Metab. 2006. PMID: 16502124 Review. No abstract available.

6

Regulation of parathyroid function in chronic kidney disease (CKD).

Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T. Fukagawa M, et al. Clin Exp Nephrol. 2006 Sep;10(3):175-9. doi: 10.1007/s10157-006-0432-9. Clin Exp Nephrol. 2006. PMID: 17009074 Review.

7

[Role of the kidney in mineral metabolism].

Fukagawa M, Akizawa T. Fukagawa M, et al. Nihon Jinzo Gakkai Shi. 2007;49(4):404-5. Nihon Jinzo Gakkai Shi. 2007. PMID: 17578183 Japanese. No abstract available.

8

Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.

Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 study group. Fukagawa M, et al. Nephrol Dial Transplant. 2008 Jan;23(1):328-35. doi: 10.1093/ndt/gfm534. Epub 2007 Aug 23. Nephrol Dial Transplant. 2008. PMID: 17717030 Clinical Trial.

9

Direct injection of calcitriol or its analog improves abnormal gene expression in the hyperplastic parathyroid gland in uremia.

Shiizaki K, Fukagawa M, Yuan Q, Hatamura I, Nii-Kono T, Saji F, Shigematsu T, Akizawa T. Shiizaki K, et al. Among authors: fukagawa m. Am J Nephrol. 2008;28(1):59-66. doi: 10.1159/000109240. Epub 2007 Sep 28. Am J Nephrol. 2008. PMID: 17901691

10

Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.

Komaba H, Fukagawa M; KRN1493 Study Group. Komaba H, et al. Among authors: fukagawa m. Ther Apher Dial. 2008 Oct;12 Suppl 1:S44-9. doi: 10.1111/j.1744-9987.2008.00631.x. Ther Apher Dial. 2008. PMID: 19032527

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

615 results

Search Page